Stoke Therapeutics Reports Second Quarter Financial Results

– STK-001: Additional data from patients treated with single and multiple doses along with data from open-label extension studies anticipated in Q1 2024 –


– STK-001: Company plans to share...

Related Keywords

Denmark , Cambridge , Cambridgeshire , United Kingdom , United States , Italy , Ireland , Massachusetts , Bedford , Dublin , American , Edwardm Kaye , , Stoke Therapeutics Inc , Acadia Pharmaceuticals , American Epilepsy Society , Exchange Commission , Augmentation Of Nuclear Gene Output , Augmentation Of Nuclear Gene Output Is Stoke , International Epilepsy Congress , Company Annual Report On Form , Regulatory Agency , Nasdaq , Stoke Therapeutics , Chief Executive Officer , Dominant Optic Atrophy , Clinical Trial Application , United Kingdom Medicines , International Epilepsy Congress September , Year To Date Financial , Collaboration Agreement , Autosomal Dominant Optic Atrophy , Targeted Augmentation , Nuclear Gene Output , Private Securities Litigation Reform Act , Annual Report , Months Ended June , Markets ,